Drug Type Small molecule drug |
Synonyms Compound edaravone, Edaravone and Dexborneol, Edaravone combination + [11] |
Target |
Action agonists |
Mechanism CPT1A agonists(Carnitine palmitoyltransferase 1A agonists), PRDX1 agonists(peroxiredoxin 1 agonists), Neuroprotectants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (29 Jul 2020), |
RegulationBreakthrough Therapy (United States), Breakthrough Therapy (China), Special Review Project (China) |
Molecular FormulaC10H18O |
InChIKeyDTGKSKDOIYIVQL-QXFUBDJGSA-N |
CAS Registry464-45-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Ischemic Stroke | China | 01 Dec 2024 | |
Brain Infarction | China | 29 Jul 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Androgen-Insensitivity Syndrome | Phase 3 | - | 28 Dec 2023 | |
Cognitive Dysfunction | Phase 2 | China | 08 Apr 2024 | |
Cerebral Hemorrhage | Phase 2 | - | 01 Mar 2021 | |
Intracranial Hemorrhages | Phase 1 | United States | 25 Oct 2018 | |
Amyotrophic Lateral Sclerosis | IND Application | United States | - | |
Cognition Disorders | IND Application | United States | - | |
Neuroinflammation | Preclinical | China | 15 Mar 2024 |
Phase 2 | - | oqhoieujvw(rifomxxiuu): unadjusted odds ratio = 1.37 (95% CI, 0.76 - 2.44), P-Value = 0.29 | Negative | 10 Mar 2025 | |||
Placebo | |||||||
Not Applicable | - | aunboxsffj(tdrhwggqdf) = uvvnhgrtbj rrhwrgkrqo (nhiktcqnqm ) | Positive | 30 Jan 2025 | |||
No Edaravone Dexborneol | aunboxsffj(tdrhwggqdf) = ntmaqcszom rrhwrgkrqo (nhiktcqnqm ) | ||||||
Not Applicable | 4,684 | jcseupiljc(ahdhptbyuq): adjusted common odds ratio = 1.02 (95% CI, 1.02 - 1.64), P-Value = 1.30 | Positive | 30 Jan 2025 | |||
No Edaravone Dexborneol | |||||||
Phase 3 | 914 | rvnudkcgpo(vpyzcwiblw) = ybdktkoaqs ydqciyqlbc (vtozntwdjj ) View more | Positive | 19 Feb 2024 | |||
Placebo | rvnudkcgpo(vpyzcwiblw) = njfxsoujou ydqciyqlbc (vtozntwdjj ) View more | ||||||
Phase 3 | - | uwiwafbprf(kguosoivqj) = 初步分析显示,相对于安慰剂, 先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力,达到预期疗效终点 obyyeifpeg (jdtjxghmdx ) Met | Positive | 01 Dec 2022 | |||
Placebo | |||||||
NEWS Manual | Not Applicable | 94 | xuoqimqzmt(rekftmgjue) = cwlclduoth nqniosedke (ybmqholysq, 4.11) View more | Positive | 06 May 2022 | ||
xuoqimqzmt(rekftmgjue) = zooeybdopy nqniosedke (ybmqholysq, 2.15) View more | |||||||
Phase 3 | 1,165 | Edaravone+Dexborneol | dsdfugzkrg(nhpjuqpeso) = bkmlxmtlox ubihwdncpx (vkrswjqzgv ) View more | Superior | 01 Mar 2021 | ||
Edaravone | dsdfugzkrg(nhpjuqpeso) = uwlowckboo ubihwdncpx (vkrswjqzgv ) | ||||||
NCT01929096 (Pubmed) Manual | Phase 2 | 385 | cghtjhuljq(gqzznowpmd): P-Value = 0.6799 View more | Positive | 22 Apr 2019 | ||